Study Title | AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma |
---|---|
Protocol ID | AOST2032 |
Disease (Sub Disease) | High Grade Osteosarcoma Localized Osteosarcoma Metastatic Osteosarcoma Secondary Osteosarcoma |
Diagnosis Stage | Newly diagnosed |
Location | NSW / VIC / NZ |
Sponsor | National Cancer Institute (NCI) |
Links | https://clinicaltrials.gov/ct2/show/NCT05691478 |
Trial Status | Open |
Sites | Royal Children's Hospital / Christchurch Children's Hospital/ Sydney Children's Hospital |
Study Type | Treatment |
Phase | Phase 2/3 |
Age Eligibility | up to 40 Years |
International registry ID's | NCT05691478 |